BREAKING NEWS: Avania, a leading global MedTech advisory and clinical development partner, has just announced the appointment of four new executives to its leadership team, a move aimed at enhancing its capabilities in a rapidly evolving industry. This strategic shift comes as the MedTech sector faces increasing regulatory complexities and technological advancements.
Effective September 4, 2025, the newly appointed executives bring a wealth of experience that promises to bolster Avania’s mission to deliver expert-driven solutions. The appointments include:
– **Angela Johnson**, PhD, RAC, Senior Vice President, Advisory Services. With over **25 years** in regulatory strategy and clinical development, Dr. Johnson will spearhead Avania’s global advisory practice, aiding MedTech innovators in navigating complex regulatory frameworks across the **FDA**, **EU**, and **Asia-Pacific** regions.
– **Paul Southam**, Chief Information Officer. Southam steps into the role with **over 20 years** of global experience in IT and digital transformation, tasked with aligning technology with business objectives to drive operational efficiency and innovation.
– **Marianne Martin**, Vice President, Global Project Management. Bringing **20 years** of expertise in clinical research operations, Martin will oversee Avania’s project management teams, ensuring that complex, multi-center clinical trials are executed with precision.
– **Karen Auten**, Vice President, Global Clinical Operations. Auten, recognized for her leadership in clinical trial management, will lead the execution of clinical trials from first-in-human through post-market studies, reinforcing Avania’s commitment to clinical innovation.
Jason Monteleone, CEO of Avania, emphasized the significance of these appointments, stating, “These appointments mark an exciting chapter in Avania’s evolution as we scale to meet increasing global demand for MedTech regulatory and clinical expertise.” His comments highlight the urgency and importance of these new leadership roles in addressing the dynamic healthcare landscape.
Avania’s commitment to enhancing its global presence is evident as it aims to deliver comprehensive clinical research and regulatory solutions. The additions to the leadership team will enable Avania to better assist clients in navigating the complexities of bringing innovative medical technologies to market.
As the MedTech industry continues to evolve, the implications of these appointments will be closely monitored. Avania’s strengthened leadership position underscores its goal to remain at the forefront of clinical development and regulatory advisory services.
For ongoing updates and more information, visit www.avaniaclinical.com.
This announcement highlights Avania’s proactive approach to adapting to industry challenges and its dedication to improving patient health and well-being through innovative solutions.
